Open-Angle Glaucoma - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 123
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OEE13D4E0D4EN
Leaflet:

Download PDF Leaflet

Open-Angle Glaucoma - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Open-Angle Glaucoma - Pipeline Review, H2 2016’, provides an overview of the Open-Angle Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
  • The report reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Open-Angle Glaucoma therapeutics and enlists all their major and minor projects
  • The report assesses Open-Angle Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Open-Angle Glaucoma Overview
Therapeutics Development
Pipeline Products for Open-Angle Glaucoma - Overview
Pipeline Products for Open-Angle Glaucoma - Comparative Analysis
Open-Angle Glaucoma - Therapeutics under Development by Companies
Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes
Open-Angle Glaucoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Open-Angle Glaucoma - Products under Development by Companies
Open-Angle Glaucoma - Products under Investigation by Universities/Institutes
Open-Angle Glaucoma - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals, Inc.
Allergan Plc
Amakem NV
Bausch & Lomb Incorporated
F. Hoffmann-La Roche Ltd.
Glaukos Corporation
Inotek Pharmaceuticals Corporation
Isarna Therapeutics GmbH
Kowa Company, Ltd.
Laboratoires Thea S.A.
Laboratorios Sophia S.A. de C.V.
Lee's Pharmaceutical Holdings Limited
Lexicon Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Otsuka Holdings Co., Ltd.
Oxford BioMedica Plc
Sanofi
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Sylentis S.A.U.
ViSci Ltd.
Open-Angle Glaucoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(bimatoprost + timolol maleate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(carteolol hydrochloride + latanoprost) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(latanoprost + netarsudil mesylate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(latanoprost + timolol maleate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(latanoprost + trabodenoson) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMA-0076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bamosiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimatoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimatoprost SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DE-117 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glaucoma-GT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprostene bunod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levobetaxolol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LX-7101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGV-354 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netarsudil mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPA-6566 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRO-067 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-4929 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ripasudil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5093151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-366234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sepetaprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNJ-1656 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trabodenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
travoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
travoprost SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
travoprost XR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Open-Angle Glaucoma - Dormant Projects
Open-Angle Glaucoma - Discontinued Products
Open-Angle Glaucoma - Product Development Milestones
Featured News & Press Releases
Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension
Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting
Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week
Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System
Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Open-Angle Glaucoma, H2 2016
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Investigation by Universities/Institutes, H2 2016
Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016
Open-Angle Glaucoma - Pipeline by Allergan Plc, H2 2016
Open-Angle Glaucoma - Pipeline by Amakem NV, H2 2016
Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2016
Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Open-Angle Glaucoma - Pipeline by Glaukos Corporation, H2 2016
Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016
Open-Angle Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2016
Open-Angle Glaucoma - Pipeline by Kowa Company, Ltd., H2 2016
Open-Angle Glaucoma - Pipeline by Laboratoires Thea S.A., H2 2016
Open-Angle Glaucoma - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016
Open-Angle Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Open-Angle Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2016
Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Open-Angle Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2016
Open-Angle Glaucoma - Pipeline by Sanofi, H2 2016
Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
Open-Angle Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016
Open-Angle Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
Open-Angle Glaucoma - Pipeline by Sylentis S.A.U., H2 2016
Open-Angle Glaucoma - Pipeline by ViSci Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Open-Angle Glaucoma - Dormant Projects, H2 2016
Open-Angle Glaucoma - Dormant Projects (Contd.1), H2 2016
Open-Angle Glaucoma - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Open-Angle Glaucoma, H2 2016
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Aerie Pharmaceuticals, Inc.
Allergan Plc
Amakem NV
Bausch & Lomb Incorporated
F. Hoffmann-La Roche Ltd.
Glaukos Corporation
Inotek Pharmaceuticals Corporation
Isarna Therapeutics GmbH
Kowa Company, Ltd.
Laboratoires Thea S.A.
Laboratorios Sophia S.A. de C.V.
Lee's Pharmaceutical Holdings Limited
Lexicon Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Otsuka Holdings Co., Ltd.
Oxford BioMedica Plc
Sanofi
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Sylentis S.A.U.
ViSci Ltd.
Skip to top


Glaucoma - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 298 pages

Ask Your Question

Open-Angle Glaucoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: